Disrupting cancer through SurVaxM immunotherapy
At MimiVax, our mission is to disrupt cancer. We are dedicated to improving survival and sending hope to cancer patients
News and Events
MimiVax LLC and Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. announce exclusive licensing agreement on SurVaxM for glioblastoma treatment in China
Under terms of the agreement, Fosun Pharma and MimiVax will seek to clinically develop and commercialize SurVaxM to make it available for patients in specified territories in China.
November 18, 2019
MimiVax to present results of SurVaxM in glioblastoma at ASCO 2019 Meeting
Updated median progression free survival (mPFS) is 15.5 months from diagnosis. Median overall survival (OS) is at 30.5 months from diagnosis. SurVaxM immunotherapy generated encouraging efficacy and immunogenicity in glioblastoma with minimal toxicity.
June 05, 2019
Mimivax looks for game-changer in GBM as Survaxm shows signal at interim look
In the ongoing study, survival trends strengthened as the data have matured. With the phase II in nGBM so far achieving a survival rate that exceeds the historical standard of care by 40 percent, the study already met its six-month PFS endpoint.
May 21, 2018
Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates
MimiVax is improving outcomes and quality of life for those suffering from devastating diseases as well as strengthening the biomedical startup ecosystem of Buffalo, New York.
We’re exploring new ways of stimulating the immune system to fight cancer cells leveraging our proprietary survivin-targeting technology.
SurVaxM is presently being studied in glioblastoma (newly diagnosed and recurrent), multiple myeloma and neuroendocrine tumors (NET).
“The Jacobs family has a deep passion for the discovery of new drugs and medical devices that will help ease the suffering and offer improved treatments for patients diagnosed with chronic and terminal diseases.”
To disrupt cancer with innovative immunotherapies
SurVaxM is currently being evaluated in: a Phase II clinical trial in adults with newly diagnosed glioblastoma; a Phase I clinical trial in combination with REVLIMID® (lenalidomide) for adults with multiple myeloma; and a Phase I clinical trial for metastatic neuroendocrine tumors (NET).
Partner with us
MimiVax is a privately held, clinical-stage biotechnology company that was formed in 2012 from Roswell Park Comprehensive Cancer Center. This was quickly followed by a prestigious award from the American Cancer Society, and support from the Roswell Park Alliance Foundation enabling clinical studies of SurVaxM for glioblastoma. If you are an investor interested in MimiVax, please reach out via the contact form below.
MimiVax is a team of experienced scientists, leading clinicians and industry leaders.
We are committed to pursuing the most efficient and comprehensive path to deliver upon the promise of SurVaxM to improve the lives of those battling cancer.